{"name":"Caicun Zhou","slug":"caicun-zhou","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPSG1SVDZ5azZpakhhSDMtSHNBWl95SktCZE1ubXZlVTh6UDFuV2lnbDJveFhSYzdhM2lLTTdGbW5JS2pRZUpiTllaSnpvY1pfUUQzbTVRa3hnbGFkMkF1dkk4bnU4a1BRRFh0SlBlMklNQ2hRZmhkbzdQeVF1VjVFSVhodGhuRW9RWHJKS3NSMHhFWXk0aXJnSm1OLUs5NEtmUXhhWUtPX1d0MVByNVJhUjAwLVpDSzFueW5XcFNDOWc0UVNVa0FzN1hn?oc=5","date":"2025-07-29","type":"regulatory","source":"ascopost.com","summary":"Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC - ascopost.com","headline":"Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPSW9KTmd0amdaLXNadFM5WlJHYVdFTkE5OEw3Z1RCVlhfNUFzMUZrTGIwY25uTWtNUDY1bjlkU0xfSGduWnhzUlFqYk5qa1VYMGE3YWlIdFZBQklEczAyQXFmOENrT2pKRmVFckcxQjRUOXkzSnJ2cXRXNWxDbmgydnZXQTRaRHJJbGFZZnk3dEwyZ0RRYzJBbU9lSUE1bXd2TlpTNWx6ZlVsSlpldmRsMm92Nzg?oc=5","date":"2024-09-25","type":"pipeline","source":"ascopost.com","summary":"HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC - ascopost.com","headline":"HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNby1pMTUyVjBYQjNLcEV1NUh2Q0RqTzdKT043Mm13QWZwdmFlTHVaRkpMRm9aM3RDalVfQzZ2ZFJUZXhrMXAxeGV4aVZjcVBRQmNBLS1URzJuZUEwLVFIMnA5SVJWcU9LUlMxQkJMX2FSV0U2VEsyeXpiMXozYUh1Mg?oc=5","date":"2024-09-09","type":"trial","source":"pharmaphorum","summary":"WCLC: Summit trumpets data with Keytruda challenger - pharmaphorum","headline":"WCLC: Summit trumpets data with Keytruda challenger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS3lRam1BcVBrX21SRHY2TkNBbkJEZnJ0enkwSTU3Q0JOM0hhVUg2ZFV1dlhreVFHY3RpNUhDNXZ5SWplTXdWMnBsdzNXWnBlc0d6R2hVdHJBZ1RGYW1MdlN5SjhvMU91MG1ST1Q2WWxCSHpjaWJXdHBrYW16czRiY2VuU0Y3bk1yaGNiOHI0U1c0b1AtVHdpZ0dZWnkweS1GTXZmczJ1T0doTXNNb3pJcGlB?oc=5","date":"2024-09-08","type":"trial","source":"Fierce Pharma","summary":"Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer - Fierce Pharma","headline":"Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQY3BtR2MzYVZuV0ZMZll0UDJlLTZPdHpfOFNxdnZLSmtrR2dPZ2xvYkVTc3EtSVFPYUNSZ2pfaFhKNXdsYm5kTXoyTWFVSmdfOVVqWWptV2V5MU5Md0Y1WDV2OWY2eVVNQnpXTUlPd2xIc2VNOV9MWFU0elc0MGhtWWdEcGJWNDAzdEIta18yQ1FhUHl6T1QzVTBBU25MeVU5eFQ5VExlMjVZbzJ3cTlhNw?oc=5","date":"2024-09-08","type":"pipeline","source":"OncLive","summary":"Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC - OncLive","headline":"Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE16c1pjZ2VxbV92T2k4d0JMbTU0MjVSS3AwSEtpM2RIUTByOGFKWFFrVnFLcDNTOWtsb2ZFWWx2djhXdUJ1RGMxTzRzTHdKRnVDTWFib0ZnS1VacXFQYmtnTy13V2JhT01zeTdVQzdTVVJ3Zw?oc=5","date":"2021-10-14","type":"regulatory","source":"MedPage Today","summary":"Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs - MedPage Today","headline":"Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBRdWUxSnQ1UzYwSjRZMG1pYXpEQVY3UERCR3pxb2lENFJFcVNwRWN6OVd3VmtUSDJrT1Z0NnlOY0ZCVUVDbUVhT0V1d2RHYXlsYVVaWklYZlZhbmJoOUR2WDc4ZUNfQjRCM2lXX0xR0gFyQVVfeXFMTkk1aDFDemJodWV4OTJyc2JGUm54a0VrVzJTRGZNM2JYdjBFUTRtVm9FN1g3YUJQS3d5cFJRRXlxdU5PWXZ6ZUg3WTZWT2Z0eTV4QzRrczA3SkdWdGhhR3YyMlFZWjNnZTlwV2F4MVJZdjZR?oc=5","date":"2021-04-13","type":"trial","source":"koreabiomed.com","summary":"Trial results of Chinese immunotherapy tislelizumab unveiled at AACR meet - koreabiomed.com","headline":"Trial results of Chinese immunotherapy tislelizumab unveiled at AACR meet","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}